FocusPolicy

Tuberculosis vaccines: Time for a global strategy

See allHide authors and affiliations

Science Translational Medicine  25 Feb 2015:
Vol. 7, Issue 276, pp. 276fs8
DOI: 10.1126/scitranslmed.aaa4730

Figures

  • Fig. 1 New knowledge drives acceleration.

    Current clinical trials are restricted to analyzing canonical measures considered relevant to safety and efficacy. Because of the lack of correlates of protection for TB, researchers need new information that likely can be provided by global omics profiling. Data are generated from observational studies that analyze disease severity and disease risk in naturally Mtb-infected individuals and from vaccine clinical trials that focus on signatures of safety and efficacy. Through computational data analysis and modeling, new information can be harnessed to improve vaccine candidates entering the clinical trial pipeline and to design new vaccination strategies.

    CREDITS: H. McDONALD/SCIENCE TRANSLATIONAL MEDICINE; CDC PUBLIC HEALTH IMAGE LIBRARY

Navigate This Article